EUVIMEDEUVIMED entdecken
Crossref

Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study

Yet H Khor iD, Max Schulte, Kerri A Johannson iD, Veronica Marcoux, Jolene H Fisher, Deborah Assayag iD, Helene Manganas, Nasreen Khalil, Martin Kolb iD, Christopher J Ryerson, Austin ILD Registry and CARE-PF Investigators, ALLIANCE Study Group und 12 weitere

European Respiratory Journal · 2023

DOI: 10.1183/13993003.02163-2022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Respiratory Journal, 2023. Verfasst von Yet H Khor und 23 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Research@Alfred, Central Clinical School, Monash University, Melbourne, Australia yet.khor@monash.edu. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Boehringer Ingelheim, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Little is known about generalisability of randomised controlled trials (RCTs) for idiopathic pulmonary fibrosis (IPF). We evaluated eligibility criteria for phase III IPF RCTs to determine their representativeness in clinical registries, and calculated forced vital capacity (FVC) changes according to eligibility criteria.

Methods

Common eligibility criteria used in >60% of IPF RCTs were identified from a literature search and applied to patients with IPF from prospective Australian and Canadian registries. Additional pre-specified criteria of 6-min walk distance (6MWD) and different measures of preceding disease progression were also evaluated. Joint longitudinal-survival modelling was used to compare FVC decline according to eligibility for individual and composite criteria.

Results

Out of 990 patients with IPF, 527 (53%) met all common RCT eligibility criteria at the first clinic visit, including 343 with definite IPF and 184 with radiological probable usual interstitial pneumonia pattern without histological confirmation ( i.e. provisional IPF). The percentages of eligible patients for landmark RCTs of nintedanib and pirfenidone were 19–50%. Adding 6MWD ≥150 m and different measures of preceding disease progression to the composite common criteria reduced the percentages of patients meeting eligibility to 52% (n=516) and 4–18% (n=12–61), respectively. Patients meeting the composite common criteria had less-rapid 1-year FVC decline than those who did not (−90 versus −103 mL, p=0.01). Definite IPF generally had more-rapid 1-year FVC decline compared to provisional IPF.

Conclusions

Eligibility criteria of previous IPF RCTs have limited generalisability to clinical IPF populations, with FVC decline differing between eligible and ineligible populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic Pulmonary FibrosisHumansAustraliaCanadaVital CapacityDisease ProgressionPyridonesRegistriesPharmaceutical PreparationsTreatment OutcomeRandomized Controlled Trials as Topic

Substanzen

PyridonesPharmaceutical Preparations

Autor:innen und Institutionen

  • Respiratory Research@Alfred, Central Clinical School, Monash University, Melbourne, Australia yet.khor@monash.edu.
  • Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Australia.
  • Institute for Breathing and Sleep, Heidelberg, Australia.
  • Faculty of Medicine, University of Melbourne, Melbourne, Australia.
  • School of Health Sciences, Swinburne University of Technology, Melbourne, Australia.
  • Department of Medicine, University of Calgary, Calgary, AB, Canada.

ORCID-Profile: Yet H Khor, Kerri A Johannson, Deborah Assayag, Martin Kolb

Förderung

  • Boehringer Ingelheim
  • National Health and Medical Research Council

Zitieren

APA

Khor, Y. H., Schulte, M., Johannson, K. A., Marcoux, V., Fisher, J. H., Assayag, D., Manganas, H., Khalil, N., Kolb, M., Ryerson, C. J., Austin ILD Registry and CARE-PF Investigators, ALLIANCE Study Group, Cox, G., Fell, C. D., Gershon, A. S., Goh, N., Halayko, A. J., Lok, S., Morisset, J., …, & Wong, A. W. (2023). Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study. European Respiratory Journal. https://doi.org/10.1183/13993003.02163-2022

Vancouver

Khor YH, Schulte M, Johannson KA, Marcoux V, Fisher JH, Assayag D, et al. Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study. European Respiratory Journal. 2023. doi:10.1183/13993003.02163-2022

BibTeX
@article{Khor2023,
  author = {Khor, Yet H and Schulte, Max and Johannson, Kerri A and Marcoux, Veronica and Fisher, Jolene H and Assayag, Deborah and Manganas, Helene and Khalil, Nasreen and Kolb, Martin and Ryerson, Christopher J and Austin ILD Registry and CARE-PF Investigators, Austin ILD Registry and CARE-PF Investigators and ALLIANCE Study Group, ALLIANCE Study Group and Cox, Gerard and Fell, Charlene D and Gershon, Andrea S and Goh, Nicole and Halayko, Andrew J and Lok, Stacey and Morisset, Julie and Sadatsafavi, Mohsen and Shapera, Shane and To, Teresa and Wilcox, Pearce G and Wong, Alyson W},
  title = {Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study},
  journal = {European Respiratory Journal},
  year = {2023},
  doi = {10.1183/13993003.02163-2022}
}
Kostenlos starten →